RAD media and Publications, page-56

RAD 301 - Media release. Positive new publication in Cancer Biotherapy and Radiopharmaceuticals.

Interesting that on the RAD website pipeline RAD-301 is still listed as preclinical with IND approved 12/22 yet abstract is validation in 20 patients.

"The results included intense uptake of radiotracer in the tumor with no uptake in healthy tissues. It was also observed that PET/CT imaging at 60 minutes post injection was the optimal time for imaging the tumors with 68Ga-Trivehexin"

"The abstract concluded that 68Ga-Trivehexin is an extremely promising agent for non-invasive molecular imaging of Integrin αVβ6 expressing tumors"

RAD 301 is a priority for H1 as per RAD pipeline on their website. Great to see another asset looking "extremely promising" as a imaging/diagnostic and therapeutic. The imaging trials are quick which is why it has been so swift to trial in 20 patients from IND in only 12/22. This further reinforces this solid investment as another drug presents great data in it's early stages. The imaging windfall once commercialised like we have seen projected for pivalate offer a great early cash run rate while the therapeutic versions of the drug are still in trials.






Abstract here - https://radiopharmtheranostics.us5.list-manage.com/track/click?u=2020b74e9b9a298e9cadee03b&id=53b9af44f7&e=4b070d4bfe